"We're very pleased to have reached this agreement with Royalty Pharma," said Eugene S. Sunshine, Northwestern's Senior Vice President for business and finance. "Beginning with the original research done at Northwestern, the development of LYRICA® has brought relief to thousands of patients worldwide. This exemplifies the type of cutting-edge research that is occurring at Northwestern."

"Essentially, we are converting a potential stream of future royalty revenues from LYRICA® into an immediate cash payment," Sunshine explained. "We continue to believe strongly in LYRICA's potential and Northwestern retains a large portion of those royalty rights, but by doing this, we are diversifying the University's investments."

Approved applications

LYRICA® is indicated to treat Diabetic Nerve Pain, Post Shingles Pain and Fibromyalgia. LYRICA® is also indicated to treat Partial Onset Seizures in adults with epilepsy who take one or more drugs for seizures, Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Onset Seizures and Fibromyalgia.

Applications in development

CNS (Restless Leg Syndrome, Post Operative Pain)

Therapeutic Area

CNS (Diabetic Peripheral Neuropathy)
Postherpetic Neuralgia
Central Neuropathic Pain (Europe)
Generalized Anxiety Disorder (Europe)
Fibromyalgia (US)

Acquisition Date

Dec 2007